Novavax Expects Vaccinations to Begin in U.K. in April: CEO

The transcript discusses the process and challenges of applying for emergency use authorization for a COVID-19 vaccine in the US and UK. It covers the efficacy results from trials in South Africa and the UK, highlighting the lower efficacy in HIV-positive patients. The conversation also touches on the need for vaccine reformulation to address mutations and the complexities of global vaccine distribution. The potential impact of the Brazil variant on trials is also mentioned.

What are the concerns regarding the lower efficacy in HIV positive patients?

What strategies are being discussed to combine COVID-19 vaccines with flu vaccines?

What is the company's approach to regulatory approval in different regions?

How does the company plan to ensure global vaccine distribution?